When integrating CKD-MBD management, it is vital to consider not only serum phosphate but also calcium levels, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23), as these biomarkers inform phosphorus targets and treatment intensity [44]. The gene discussed is PTH; the disease is Marchiafava-Bignami disease.